Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-021747
Filing Date
2022-04-27
Accepted
2022-04-27 06:04:17
Documents
5
Period of Report
2022-04-27

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea158916-6k_nlspharm.htm 6-K 10784
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. ANNOUNCES CLOSING OF US$4.4 MILLIO ea158916ex99-1_nlspharm.htm EX-99.1 14274
3 GRAPHIC image_001.jpg GRAPHIC 4418
4 GRAPHIC image_002.jpg GRAPHIC 4418
5 GRAPHIC image_003.jpg GRAPHIC 4418
  Complete submission text file 0001213900-22-021747.txt   44730
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 22856141
SIC: 2834 Pharmaceutical Preparations